Functional and Physical Interactions between AML1 Proteins and an ETS Protein, MEF: Implications for the Pathogenesis of t(8;21)-Positive Leukemias

ABSTRACT The AML1 and ETS families of transcription factors play critical roles in hematopoiesis; AML1, and its non-DNA-binding heterodimer partner CBFβ, are essential for the development of definitive hematopoiesis in mice, whereas the absence of certain ETS proteins creates specific defects in lymphopoiesis or myelopoiesis. The promoter activities of numerous genes expressed in hematopoietic cells are regulated by AML1 proteins or ETS proteins. MEF (for myeloid ELF-1-like factor) is a recently cloned ETS family member that, like AML1B, can strongly transactivate several of these promoters, which led us to examine whether MEF functionally or physically interacts with AML1 proteins. In this study, we demonstrate direct interactions between MEF and AML1 proteins, including the AML1/ETO fusion protein, in t(8;21)-positive acute myeloid leukemia (AML) cells. Using mutational analysis, we identified a novel ETS-interacting subdomain (EID) in the C-terminal portion of the Runt homology domain (RHD) in AML1 proteins and determined that the N-terminal region of MEF was responsible for its interaction with AML1. MEF and AML1B synergistically transactivated an interleukin 3 promoter reporter gene construct, yet the activating activity of MEF was abolished when MEF was coexpressed with AML1/ETO. The repression by AML1/ETO was independent of DNA binding but depended on its ability to interact with MEF, suggesting that AML1/ETO can repress genes not normally regulated by AML1 via protein-protein interactions. Interference with MEF function by AML1/ETO may lead to dysregulation of genes important for myeloid differentiation, thereby contributing to the pathogenesis of t(8;21) AML.

[1]  A. Bassuk,et al.  A direct physical association between ETS and AP-1 transcription factors in normal human T cells. , 1995, Immunity.

[2]  F. Alt,et al.  Increased T-cell apoptosis and terminal B-cell differentiation induced by inactivation of the Ets-1 proto-oncogene , 1995, Nature.

[3]  M. Marín‐Padilla,et al.  Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[4]  J. Licht,et al.  Transcription factors, normal myeloid development, and leukemia. , 1997, Blood.

[5]  J. Downing,et al.  The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation. , 1998, Molecular and cellular biology.

[6]  M. Krangel,et al.  c-Myb and core-binding factor/PEBP2 display functional synergy but bind independently to adjacent sites in the T-cell receptor delta enhancer , 1995, Molecular and cellular biology.

[7]  J. Bushweller,et al.  Biochemical and biophysical properties of the core-binding factor alpha2 (AML1) DNA-binding domain. , 1996, Journal of Biological Chemistry.

[8]  J. Rowley,et al.  Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Y. Yazaki,et al.  Generation of the AML1‐EVI‐1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. , 1994, The EMBO journal.

[10]  M. Ohki,et al.  The t(8;21) translocation in acute myeloid leukemia results in production of an AML1‐MTG8 fusion transcript. , 1993, The EMBO journal.

[11]  T. Hoshino,et al.  ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[12]  G. Thomas,et al.  Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours , 1992, Nature.

[13]  J. Gergen,et al.  Conservation and function of the transcriptional regulatory protein Runt. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Zhang,et al.  The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. , 1995, Oncogene.

[15]  F. Calabi,et al.  Leukaemia/Drosophila homology , 1992, Nature.

[16]  A. Friedman,et al.  Core binding factor cannot synergistically activate the myeloperoxidase proximal enhancer in immature myeloid cells without c-Myb , 1997, Molecular and cellular biology.

[17]  J. Rowley,et al.  AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. , 1995, Blood.

[18]  Todd R. Golub,et al.  Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation , 1994, Cell.

[19]  J. Downing,et al.  AML1, the Target of Multiple Chromosomal Translocations in Human Leukemia, Is Essential for Normal Fetal Liver Hematopoiesis , 1996, Cell.

[20]  F. Alt,et al.  The CBFβ Subunit Is Essential for CBFα2 (AML1) Function In Vivo , 1996, Cell.

[21]  M. Ohki,et al.  Interaction and functional cooperation of the leukemia‐associated factors AML1 and p300 in myeloid cell differentiation , 1998, The EMBO journal.

[22]  A. Jakubowiak,et al.  The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1 , 1999, Oncogene.

[23]  N. Lenny,et al.  The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation , 1995, Molecular and cellular biology.

[24]  J. Bushweller,et al.  Biochemical and Biophysical Properties of the Core-binding Factor α2 (AML1) DNA-binding Domain* , 1996, The Journal of Biological Chemistry.

[25]  F. Alt,et al.  The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. , 1996, Cell.

[26]  S. Hiebert,et al.  Indirect and direct disruption of transcriptional regulation in cancer: E2F and AML-1. , 1995, Critical reviews in eukaryotic gene expression.

[27]  L. Wiedemann,et al.  The novel activation of ABL by fusion to an ets-related gene, TEL. , 1995, Cancer research.

[28]  Y. Kanno,et al.  A novel transcript encoding an N-terminally truncated AML1/PEBP2 alphaB protein interferes with transactivation and blocks granulocytic differentiation of 32Dcl3 myeloid cells , 1997, Molecular and cellular biology.

[29]  D. Le Paslier,et al.  The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. , 1995, Blood.

[30]  R Grosschedl,et al.  ALY, a context-dependent coactivator of LEF-1 and AML-1, is required for TCRalpha enhancer function. , 1997, Genes & development.

[31]  Alfred L. Fisher,et al.  Groucho-dependent and -independent repression activities of Runt domain proteins , 1997, Molecular and cellular biology.

[32]  F. Collins,et al.  Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. , 1993, Science.

[33]  J. Zhang,et al.  AML1A and AML1B can transactivate the human IL-3 promoter. , 1997, Journal of immunology.

[34]  P. Sorensen,et al.  A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS–family transcription factor, ERG , 1994, Nature Genetics.

[35]  R Grosschedl,et al.  Assembly and function of a TCR alpha enhancer complex is dependent on LEF-1-induced DNA bending and multiple protein-protein interactions. , 1995, Genes & development.

[36]  G. Neale,et al.  T-cell Proto-oncogene Rhombotin-2 Is a Complex Transcription Regulator Containing Multiple Activation and Repression Domains* , 1997, The Journal of Biological Chemistry.

[37]  S Meyers,et al.  PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2 beta/CBF beta proto-oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells , 1994, Molecular and cellular biology.

[38]  D C Ward,et al.  Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[39]  D. Tenen,et al.  CCAAT Enhancer-Binding Protein ( C / EBP ) and AML 1 ( CBF a 2 ) Synergistically Activate the Macrophage Colony-Stimulating Factor Receptor Promoter , 1995 .

[40]  N. Speck,et al.  A new transcription factor family associated with human leukemias. , 1995, Critical reviews in eukaryotic gene expression.

[41]  N. Muthusamy,et al.  Defective activation and survival of T cells lacking the Ets-1 transcription factor , 1995, Nature.

[42]  M. Grunstein Histone acetylation in chromatin structure and transcription , 1997, Nature.

[43]  J. Downing,et al.  The t(8;21) Fusion Product, AML-1–ETO, Associates with C/EBP-α, Inhibits C/EBP-α-Dependent Transcription, and Blocks Granulocytic Differentiation , 1998, Molecular and Cellular Biology.

[44]  C. Wijmenga,et al.  Failure of Embryonic Hematopoiesis andLethal Hemorrhages in Mouse Embryos Heterozygousfor a Knocked-In Leukemia Gene CBFB–MYH11 , 1996, Cell.

[45]  M. Marín‐Padilla,et al.  Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene , 1997, Nature Genetics.

[46]  J. Downing,et al.  Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions , 1993, Molecular and cellular biology.

[47]  J. Zhang,et al.  MEF, a novel transcription factor with an Elf-1 like DNA binding domain but distinct transcriptional activating properties. , 1996, Oncogene.

[48]  B. Wasylyk,et al.  The Ets family of transcription factors. , 1993, European journal of biochemistry.

[49]  N. Speck,et al.  Transactivation of the Moloney murine leukemia virus and T-cell receptor beta-chain enhancers by cbf and ets requires intact binding sites for both proteins , 1995, Journal of virology.

[50]  C. Denny,et al.  A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. , 1995, Oncogene.

[51]  P. Crépieux,et al.  The Ets family of proteins: weak modulators of gene expression in quest for transcriptional partners. , 1994, Critical reviews in oncogenesis.

[52]  J. Zhang,et al.  The AML1/ETO fusion protein activates transcription of BCL-2. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[53]  N. Lenny,et al.  Functional domains of the t(8;21) fusion protein, AML-1/ETO. , 1995, Oncogene.

[54]  T. Noda,et al.  Hematopoiesis in the fetal liver is impaired by targeted mutagenesis of a gene encoding a non-DNA binding subunit of the transcription factor, polyomavirus enhancer binding protein 2/core binding factor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[55]  R. Bronson,et al.  Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta. , 1996, Proceedings of the National Academy of Sciences of the United States of America.